Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma

Overview

Journal J Cancer

Specialty Oncology

Date 2019 Apr 30

PMID 31031868

Citations 31

Authors

Huaizeng Chen

Jia Liu

Hanzhi Wang

Qi Cheng

Caiyun Zhou

Xiaojing Chen

Feng Ye

Affiliations

Soon will be listed here.

Abstract

Ovarian carcinoma (OC) is one of the most lethal malignant tumors with a high reoccurrence and chemoresistance. The key mechanism relationship with chemoresistance in ovarian carcinoma is still unclear. The existence of cancer stem cells involves in chemoresistance and reoccurrence in OC. The objective of this study was to investigate the expression, suppression of malignant properties and reversal of paclitaxel resistance inhibiting RNA-binding protein Musashi-1 with siRNA in ovarian cancer cells. The expression of MSI-1 was analyzed in 39 normal ovarian epithelia tissues, 92 serous cystadenomas, 68 borderline serous cystadenomas, and 97 serous cystadenocarcinomas by immunohistochemistry. pLKO.1-MSI-1-siRNA expression vector was transfected into ovarian carcinoma cell line A2780 and its paclitaxel-resistant cell subline A2780/Taxol. The roles of MSI-1 in proliferation, apoptosis, migration and invasion were explored by cell proliferation analysis, Caspase 3 activity assay, wound healing assay, migration and matrigel invasion assay, respectively. Western Blotting and Real-time quantitative PCR were conducted to detect the expression of MSI-1 and the ERK signaling pathway. Reversal of paclitaxel resistance assay was used to evaluate the role of MSI-1 in paclitaxel resistance of OC cells. Finally, therapeutic effects of MSI-1 inhibition were investigated the xenogratfs of SCID mice of the paclitacel-resistant. MSI-1 is overexpressed and associated with an unfavorable prognosis in OC patients. Knockdown of MSI-1 by small interfering RNA (siRNA) inhibits proliferation, promotes apoptosis, and reduces migration and invasion of cancer cells. Moreover, MSI-1 expression inhibition reverses paclitaxel-resistance in OC cells. We further display that MSI-1 effectively protects OC cells from paclitaxel-induced apoptosis by increasing the expression of p-Bcl-2 through ERK signaling pathway activation. , MSI-1 siRNA clearly showed a strong effect on tumor growth inhibition and paclitaxel-resistance reversal. These findings suggest that MSI-1 overexpression is associated with the prognosis of OC patients, and knockdown of MSI-1 can suppress malignant properties and reverse paclitaxel-resistance in OC cells. MSI-1 maybe act as a potential prognostic indicator and a therapeutic target in OC.

Citing Articles

Analysis and exploration of regulatory mechanisms and potential prognostic biomarkers in squamous cell carcinoma of the lung by expression profiling.

Wan X, Zhang C, Kang M, Rossi A, Goto T, Seetharamu N Transl Cancer Res. 2025; 14(1):569-583.

PMID: 39974402 PMC: 11833388. DOI: 10.21037/tcr-2024-2443.

Alternative splicing in ovarian cancer.

Wei L, Li Y, Chen J, Wang Y, Wu J, Yang H Cell Commun Signal. 2024; 22(1):507.

PMID: 39425166 PMC: 11488268. DOI: 10.1186/s12964-024-01880-8.

Role of the RNA-binding protein family in gynecologic cancers.

Hao L, Zhang J, Liu Z, Zhang Z, Mao T, Guo J Am J Cancer Res. 2023; 13(8):3799-3821.

PMID: 37693158 PMC: 10492115.

Surmounting Cancer Drug Resistance: New Perspective on RNA-Binding Proteins.

Feng Y, Zhu S, Liu T, Zhi G, Shao B, Liu J Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631029 PMC: 10458901. DOI: 10.3390/ph16081114.

The Musashi RNA-binding proteins in female cancers: insights on molecular mechanisms and therapeutic relevance.

Sicking M, Falke I, Loblein M, Eich H, Gotte M, Greve B Biomark Res. 2023; 11(1):76.

PMID: 37620963 PMC: 10463710. DOI: 10.1186/s40364-023-00516-2.

References

Okabe M, Imai T, Kurusu M, Hiromi Y, Okano H . Translational repression determines a neuronal potential in Drosophila asymmetric cell division. Nature. 2001; 411(6833):94-8. DOI: 10.1038/35075094. View

Imai T, Tokunaga A, Yoshida T, Hashimoto M, Mikoshiba K, Weinmaster G . The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol. 2001; 21(12):3888-900. PMC: 87052. DOI: 10.1128/MCB.21.12.3888-3900.2001. View

Okano H, Imai T, Okabe M . Musashi: a translational regulator of cell fate. J Cell Sci. 2002; 115(Pt 7):1355-9. DOI: 10.1242/jcs.115.7.1355. View

Shu H, Saito T, Watanabe H, Takeda H, Okano H, Kawata S . Expression of the Musashi1 gene encoding the RNA-binding protein in human hepatoma cell lines. Biochem Biophys Res Commun. 2002; 293(1):150-4. DOI: 10.1016/S0006-291X(02)00175-4. View

Hemmati H, Nakano I, Lazareff J, Masterman-Smith M, Geschwind D, Bronner-Fraser M . Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003; 100(25):15178-83. PMC: 299944. DOI: 10.1073/pnas.2036535100. View

Bapat S, Mali A, Koppikar C, Kurrey N . Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005; 65(8):3025-9. DOI: 10.1158/0008-5472.CAN-04-3931. View

Boyer L, Lee T, Cole M, Johnstone S, Levine S, Zucker J . Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005; 122(6):947-56. PMC: 3006442. DOI: 10.1016/j.cell.2005.08.020. View

Wang J, Rao S, Chu J, Shen X, Levasseur D, Theunissen T . A protein interaction network for pluripotency of embryonic stem cells. Nature. 2006; 444(7117):364-8. DOI: 10.1038/nature05284. View

Wang X, Yin Y, Yuan H, Sakamaki T, Okano H, Glazer R . Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways. Mol Cell Biol. 2008; 28(11):3589-99. PMC: 2423292. DOI: 10.1128/MCB.00040-08. View

10.

Gotte M, Wolf M, Staebler A, Buchweitz O, Kelsch R, Schuring A . Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma. J Pathol. 2008; 215(3):317-29. DOI: 10.1002/path.2364. View

11.

Cho K, Shih I . Ovarian cancer. Annu Rev Pathol. 2008; 4:287-313. PMC: 2679364. DOI: 10.1146/annurev.pathol.4.110807.092246. View

12.

Hartge P . Designing early detection programs for ovarian cancer. J Natl Cancer Inst. 2010; 102(1):3-4. PMC: 6284252. DOI: 10.1093/jnci/djp450. View

13.

Ye F, Li Y, Hu Y, Zhou C, Hu Y, Chen H . Expression of Sox2 in human ovarian epithelial carcinoma. J Cancer Res Clin Oncol. 2010; 137(1):131-7. DOI: 10.1007/s00432-010-0867-y. View

14.

Kharas M, Lengner C, Al-Shahrour F, Bullinger L, Ball B, Zaidi S . Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010; 16(8):903-8. PMC: 3090658. DOI: 10.1038/nm.2187. View

15.

Ito T, Kwon H, Zimdahl B, Congdon K, Blum J, Lento W . Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010; 466(7307):765-8. PMC: 2918284. DOI: 10.1038/nature09171. View

16.

Ye F, Li Y, Hu Y, Zhou C, Hu Y, Chen H . Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma. Int J Gynecol Cancer. 2010; 20(6):958-64. DOI: 10.1111/IGC.0b013e3181e6fee1. View

17.

Wang X, Penalva L, Yuan H, Linnoila R, Lu J, Okano H . Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer. 2010; 9:221. PMC: 2939568. DOI: 10.1186/1476-4598-9-221. View

18.

Rezza A, Skah S, Roche C, Nadjar J, Samarut J, Plateroti M . The overexpression of the putative gut stem cell marker Musashi-1 induces tumorigenesis through Wnt and Notch activation. J Cell Sci. 2010; 123(Pt 19):3256-65. DOI: 10.1242/jcs.065284. View

19.

Zhang J, Li Y, Zhou C, Hu Y, Chen H . Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol. 2010; 63(10):879-83. DOI: 10.1136/jcp.2009.073593. View

20.

Griner L, Reuther G . Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway. Cancer Biol Ther. 2010; 10(10):979-82. DOI: 10.4161/cbt.10.10.14010. View